Table 1.

 Patients’ profile

Group	Patient no.	Gender	Pathology	Site	Age	CS	Therapy	Response	Outcome
Resistant	1	Male	MCL	BM	82	IVA	R‐CHOP, R‐HyperCVAD	NC	Dead
	2	Male	MCL	Ascites	58	IVA	R‐CHOP, R‐HyperCVAD	PD	Dead
	3	Male	DLBCL	LN	54	IVA	R‐CHOP	PD	Dead
Sensitive	4	Male	FL	BM	75	IVA	R‐CHOP	CR	Alive
	5	Male	DLBCL	LN	61	IIIA	R‐CHOP	CR	Alive
	6	Male	DLBCL	LN	77	IIIA	R‐CHOP	CR	Alive

BM, bone marrow; CR, complete remission; CS, clinical stage; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; LN, lymph node; MCL, mantle cell lymphoma; NC, no change; PD, progressive disease; R‐CHOP, rituximab‐cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone; R‐HyperCVAD, rituximab‐hyperfractional cyclophosphamide, vincristine, adriamycin and dexamethasone.